Brief: Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide

Protagonist Therapeutics

03/03/2025 12:19

March 3 (Reuters) - Takeda Pharmaceutical 4502.T:

PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERA

PROTAGONIST THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT WITH HIGHER CLINICAL RESPONDERS ON RUSFERTIDE

PROTAGONIST THERAPEUTICS INC - ALL FOUR KEY SECONDARY ENDPOINTS MET IN VERIFY STUDY

PROTAGONIST THERAPEUTICS INC - RUSFERTIDE GENERALLY WELL TOLERATED WITH NO NEW SAFETY FINDINGS

PROTAGONIST THERAPEUTICS INC - IMPACT ON TAKEDA'S FY2024 FINANCIAL RESULTS IS IMMATERIAL

Source text: ID:nBwbPzjCsa

Further company coverage: 4502.T

 ((Reuters.Briefs@thomsonreuters.com;))